The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Https://finance.yahoo.com/news/accustem-sciences-inc-emeritusdx-announce-110000007.html
AccuStem Sciences, Inc. and EmeritusDX Announce Joint Product Development Agreement and Strategic Partnership
LONDON and PHOENIX, July 17, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, and EmeritusDX, a rapidly growing cancer diagnostics and information company, today announced the execution of an agreement wherein both companies will jointly manage scientific operations and R&D for AccuStem’s product portfolio.
Initial plans as part of the collaboration will be to immediately focus on furthering the validation of AccuStem’s core offering, StemPrintER, for patients with breast cancer.
Story continues etc
Does anyone have contact within Tiziana life sciences would appreciate if you can ask for an update there's people scaremongering know stocktwits about dilution and delisting. We're we not expectation data results?
Jimmy G, false alarm, pit lane;)
Hopefully next time but tough to hold the gains at the moment in these markets for any stock.
Just found this
https://t.co/PMX1no5Yg4
Rockz
Gentmen start your engines.
We seamed to have stalled and going to have to start from the pit lane or at the back of the grid
Am I to believe some people still don’t have their shares as well?
Hilarious
Accustem price gone up but TILS share price the same!!!!!
Accustem Sciences (ACUT)
$1.785 +0.65 (+57.27%)
Volume: 50,314
JUN 28, 2023
Gentlemen, start your engines;)
I phoned up ig this morning to see when the market was open to close my positions....50% rise.....superb......does anyone know why the rise?
Up $0.565 49.78%.& $1.70.
Interesting.
Enjoying quiet the uplift!
This share when it will pick up ? Tiziana are they doing any progress? Investors how long we have to wait for ????
Https://finance.yahoo.com/news/goldman-small-cap-research-publishes-120900842.html
BALTIMORE, MD / ACCESSWIRE / June 20, 2023 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on AccuStem Sciences Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. The Goldman report carries a price target. To view the new research report, along with disclosures and disclaimers, or to download the report in its entirety, please visit: http://bit.ly/3qPmiL6.
(that link http://bit.ly/3qPmiL6. does work and you see the full report though it’s long and I have yet to read it properly.)
Interesting! we might actually see a payday shortly.
And the automatic censoring of my post just shows the sad state of the world we live in.
i just keep thinking that tlsa intra nasal delivery system will be shown to be the most effective delivery system. my feeling also is that foralumab is 50% of the solution to treating many of the central nervous system (cns) diseases being targeted by tlsa. but there are also out there other drugs which combined with foralumab will produce the perfect ****tail. so i am surprised there are no joint research projects, perhaps foralumab cannot be used in conjunction.
Https://finance.yahoo.com/news/accustem-sciences-inc-announces-collaboration-050000535.html
I only just noticed this.
'AccuStem Sciences, Inc. Announces Collaboration Agreement with University Hospitals
AccuStem Sciences, Inc.
June 6, 2023
LONDON and PHOENIX, Ariz., June 06, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, today announced the establishment of a joint clinical collaboration agreement with University Hospitals.
Per the terms of this agreement, University Hospitals will provide tissue samples with clinical outcomes to AccuStem for research purposes. The scope of the agreement covers a multitude of different cancers but will initially focus on breast cancer cases to support further validation of the StemPrintER test. The goal of the initial project is to build on the strong foundation of data for StemPrintER by demonstrating additional clinical utility beyond identifying patients’ risk of recurrence. This next step is critical for women with early stage breast cancer because there are many tests to determine the need for chemotherapy but there are no genomic tools to inform decisions earlier in the continuum of care. StemPrintER may be able to shift this paradigm by informing physicians of the most effective approaches to surgical or radiological treatment.
“AccuStem has arrived at an important juncture as we progress toward commercializing StemPrintER,” said Wendy Blosser, Chief Executive Officer of AccuStem. “With this collaboration, we intend to expand beyond identifying a patient’s prognosis by addressing unanswered clinical questions and supporting surgeons and radiation oncologists with their treatment planning.”
AccuStem and its clinical collaborators plan to present the data obtained under this agreement at scientific conferences and to publish the findings in peer-reviewed medical journals. Those activities will help to bolster the foundation of data for StemPrintER and familiarize physicians with its utility and value in clinical decision making with the ultimate goal of improving patient outcomes and quality of life.
“We are excited to work with AccuStem on this clinical project,” said Hannah Gilmore, Division Chief, Anatomic Pathology, University Hospitals Cleveland Medical Center and Professor of Pathology, Case Western Reserve University. “I am very interested in the foundation for the StemPrintER test and think that it could have important implications for treatment planning in breast cancer and perhaps many other tumor types.”
Story continues
Interestingly I had a TILS spread bet open with spreadex at EX date which gave me accustem entitlements as well as my tils holding.
Today they have finally credited the shares to the account.
I wonder if this is just about to do something.
Over 950 days now. recent news updates show slides show they are appearing to do a roadshow with. How long between that and the raise?
I do understand now trading on Nasdaq, but I do believe clinical trial it’s take time ,God how many years years as a investor are being waiting ??
Price stuck like a glue never goes up unless down , people can invest foe reason to make money not a dead progress ..
Snooker, Now trading on NASDAQ, all the news is over there TLSA. This BB is open for chat only now, and we are very grateful for that, thanks LSE.
I sense a spike coming
I am really frustrated about this share no communication from TILS or updated since 2021 , what sort of firm is this ?